Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/lenalidomide-maintenance-after-r-chop-therapy-in-diffuse-large-b-cell-uHf7HdGPPb
References (26)
-
C. Thieblemont, B. Coiffier (2007)
Lymphoma in older patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 14
-
U. Vitolo, A. Chiappella, S. Franceschetti, A. Carella, I. Baldi, G. Inghirami, M. Spina, V. Pavone, M. Ladetto, A. Liberati, A. Molinari, P. Zinzani, F. Salvi, P. Fattori, A. Zaccaria, M. Dreyling, B. Botto, A. Castellino, A. Congiu, M. Gaudiano, M. Zanni, G. Ciccone, G. Gaidano, G. Rossi (2014)
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.The Lancet. Oncology, 15 7
-
P. Zinzani, C. Pellegrini, L. Gandolfi, V. Stefoni, F. Quirini, E. Derenzini, A. Broccoli, L. Argnani, S. Pileri, M. Baccarani (2011)
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.Clinical lymphoma, myeloma & leukemia, 11 6
-
J. Gribben, N. Fowler, F. Morschhauser (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 25
-
C. Thieblemont, H. Tilly, M. Silva, R. Casasnovas, C. Fruchart, F. Morschhauser, C. Haioun, J. Lazarovici, Anida Grosicka, A. Perrot, J. Trotman, C. Sebban, D. Caballero, R. Greil, K. Eygen, A. Cohen, H. Gonzalez, R. Bouabdallah, L. Obéric, B. Corront, B. Choufi, A. López-Guillermo, J. Catalano, A. Hoof, J. Brière, J. Cabeçadas, G. Salles, P. Gaulard, A. Bosly, B. Coiffier (2017)
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 22
-
L. Sehn, J. Donaldson, M. Chhanabhai, C. Fitzgerald, K. Gill, R. Klasa, N. Macpherson, S. O'Reilly, J. Spinelli, J. Sutherland, K. Wilson, R. Gascoyne, J. Connors (2005)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 22
-
(2007)
TM: Lenalidomide in myelodysplastic syndrome and multiple myeloma -
R. Kridel, A. Mottok, P. Farinha, S. Ben-Neriah, D. Ennishi, Yvonne Zheng, E. Chavez, H. Shulha, K. Tan, F. Chan, M. Boyle, B. Meissner, A. Telenius, L. Sehn, M. Marra, Sohrab Shah, C. Steidl, J. Connors, D. Scott, R. Gascoyne (2015)
Cell of origin of transformed follicular lymphoma.Blood, 126 18
-
T. Witzig, K. Tobinai, L. Rigacci, T. Lin, T. Ikeda, A. Vanazzi, M. Hino, Yuankai Shi, J. Mayer, L. Costa, C. Bermúdez, Jun Zhu, D. Belada, K. Bouabdallah, J. Kattan, Cassandra Wu, Jenna Fan, A. Louveau, M. Voi, F. Cavalli (2016)
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).Journal of Clinical Oncology, 34
-
A. Ferreri, M. Sassone, F. Zaja, A. Re, M. Spina, A. Rocco, A. Fabbri, C. Stelitano, M. Frezzato, C. Rusconi, R. Zambello, S. Couto, Y. Ren, A. Arcari, G. Bertoldero, A. Nonis, L. Scarfò, T. Calimeri, C. Cecchetti, Marianna Chiozzotto, S. Govi, M. Ponzoni (2017)
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.The Lancet. Haematology, 4 3
-
G. Nowakowski, B. Laplant, W. Macon, C. Reeder, J. Foran, G. Nelson, C. Thompson, C. Rivera, D. Inwards, Ivana Micallef, P. Johnston, L. Porrata, S. Ansell, R. Gascoyne, T. Habermann, T. Witzig (2015)
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
-
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
-
T. Vassilakopoulos, J. Apostolidis, M. Angelopoulou (2015)
Comment on “Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial”Haematologica, 100
-
U. Vitolo, M. Trněný, D. Belada, A. Carella, N. Chua, P. Abrisqueta, J. Demeter, I. Flinn, X. Hong, W. Kim, A. Pinto, J. Burke, Yuankai Shi, Y. Tatsumi, M. Oestergaard, M. Wenger, G. Fingerle-Rowson, O. Catalani, T. Nielsen, M. Martelli, L. Sehn (2016)
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)Blood, 128
-
(2016)
Habermann T: Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma -
G. Salles, J. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. Catalano, P. Brice, D. Caballero, C. Haioun, L. Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Fermé, Maria Silva, C. Sebban, A. Lister, J. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, H. Tilly (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialThe Lancet, 377
-
T. Feldman, A. Mato, K. Chow, Ewelina Protomastro, Kara Yannotti, P. Bhattacharyya, X. Yang, M. Donato, S. Rowley, Carolanne Carini, Marisa Valentinetti, Judith Smith, G. Gadaleta, C. Bejot, S. Stives, Mary Timberg, Sabrina Kdiry, A. Pecora, A. Beaven, A. Goy (2014)
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaBritish Journal of Haematology, 166
-
C. Gisselbrecht, N. Schmitz, N. Mounier, Devinder Gill, D. Linch, M. Trněný, A. Bosly, N. Milpied, J. Radford, N. Ketterer, O. Shpilberg, U. Dührsen, H. Hagberg, D. Ma, A. Viardot, R. Lowenthal, J. Brière, G. Salles, C. Moskowitz, B. Glass (2012)
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 36
-
Sachin Shah, Thu Tran (2012)
Lenalidomide in Myelodysplastic Syndrome and Multiple MyelomaDrugs, 67
-
P. Mondello, N. Steiner, W. Willenbacher, S. Ferrero, P. Ghione, A. Marabese, V. Pitini, S. Cuzzocrea, M. Mian (2016)
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?The oncologist, 21 9
-
T. Witzig, J. Vose, P. Zinzani, C. Reeder, R. Buckstein, J. Polikoff, R. Bouabdallah, C. Haioun, H. Tilly, P. Guo, D. Pietronigro, A. Ervin‐Haynes, M. Czuczman (2011)
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
-
J. Vose, Mei-Jie Zhang, P. Rowlings, H. Lazarus, B. Bolwell, C. Freytes, S. Pavlovsky, A. Keating, B. Yanes, K. Besien, J. Armitage, M. Horowitz, A. Bashey, I. Bence‐Bruckler, L. Burns, J. Fay, R. Gale, J. Gibson, S. Giralt, S. Goldstein, R. Herzig, W. Hiddemann, R. Martino, P. McCarthy, A. Miller, G. Milone, E. Montserrat, A. Pecora, G. Phillips, A. Rubin, D. Schenkein, P. Stiff, D. Vesole, J. Wingard (2001)
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
-
G. Imhoff, A. McMillan, M. Matasar, J. Radford, K. Ardeshna, K. Kuliczkowski, W. Kim, X. Hong, Jette Goerloev, A. Davies, M. Barrigón, M. Ogura, S. Leppä, M. Fennessy, Qiming Liao, B. Holt, S. Lisby, A. Hagenbeek (2017)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 5
-
M. Crump, S. Leppä, L. Fayad, Je Lee, A. Rocco, M. Ogura, H. Hagberg, F. Schnell, R. Rifkin, A. Mackensen, F. Offner, L. Pinter-Brown, Sonali Smith, K. Tobinai, S. Yeh, E. Hsi, Tuan Nguyen, Peipei Shi, M. Hahka‐Kemppinen, D. Thornton, B. Lin, B. Kahl, N. Schmitz, K. Savage, T. Habermann (2016)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 21
-
P. Hamlin, A. Zelenetz, T. Kewalramani, J. Qin, J. Satagopan, D. Verbel, A. Noy, C. Portlock, D. Straus, J. Yahalom, S. Nimer, C. Moskowitz (2003)
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.Blood, 102 6
-
M. Czuczman, J. Vose, T. Witzig, P. Zinzani, R. Buckstein, J. Polikoff, Ju Li, D. Pietronigro, A. Ervin-Haynes, C. Reeder (2011)
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological originBritish Journal of Haematology, 154
- Publisher
- Karger
- Copyright
- © 2017 S. Karger AG, Basel
- ISSN
- 0001-5792
- eISSN
- 1421-9662
- DOI
- 10.1159/000484515
- Publisher site
- See Article on Publisher Site
Abstract
Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved, several attempts to combine it with novel agents and/or use them as maintenance therapy failed to improve the outcome. Recently, maintenance with lenalidomide after standard immune chemotherapy showed promising results. This review discusses the most pertinent published and running studies, analyzing study design, results, and practicality.
Journal
Acta Haematologica – Karger
Published: Jan 1, 2017
Keywords: Diffuse large B-cell lymphoma; Lenalidomide; Maintenance treatment